Peptide mimetics aim to replicate the interaction between peptide and biological target while modifying non-essential regions to achieve desirable pharmacokinetic properties including enhanced stability, solubility and even potency. Replacement of cysteine bridges with synthetic isosteres1,2 and other forms of macrocyclisation have previously yielded peptide mimetics that have significant differences in biological activity.3 These analogues are important not only for the pharmaceutical development of the peptide but also for elucidation of the overarching biological importance of the target disulfide bond.2 In the native cystine-containing peptides, oxidative cyclisation of the linear sequence often appeared to be supported by suitably positioned proline residues. The peptide bond can exist in both cis and trans states, where the cis state is relatively abundant adjacent to a proline residue.4 There are remarkable examples of commercially significant peptides that have been shown to be activated by the singular cis-trans interconversion adjacent to a proline.5-7 Building upon this work, we want to explore the involvement of such transitions in new peptide classes including proline-rich antimicrobials and analgesic conotoxins with both established conformationally restricted proline analogues and novel pseudoprolines. Given our successful cyclisation approach to form sterically hindered 5,5-dimethylproline,8 interchanging our metathesis cross-partner presents a facile method of generating novel spirocyclic pseudoproline systems. In this context, there is a large scope to explore both the cis-trans directionality of novel proline analogues and the structural and biological effect that these unnatural amino acids have in target peptides.